Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

The most commonly diagnosed breast cancer (BC) subtype is characterized by estrogen
receptor (ER) expression. Treatment of this BC subtype typically involves modalities that …

Breast cancers with positive expression of Estrogen Receptor (ER+) are treated with anti-
hormone/endocrine therapy which targets the activity of the receptor, the half-life of the …

Two thirds of breast cancers express the estrogen receptor (ER), which contributes to tumor
development and progression. ER-targeted therapy is therefore widely used in breast …

Abstract Estrogen receptor-positive (ER+) breast cancer accounts for approximately 75% of
all breast cancers. Endocrine therapies, including selective ER modulators (SERMs) …

Endocrine therapy represents the first and most efficacious targeted treatment for women
with estrogen receptor-positive (ER+) breast cancer. In the last four decades several …

The estrogen receptor (ER) pathway plays a critical role in breast cancer development and
progression. Endocrine therapy targeting estrogen action is the most important systemic …

Introduction The majority of breast cancers (BCs) are characterized by the expression of
estrogen receptor alpha (ERα+). ERα acts as ligand-dependent transcription factor for genes …

The estrogen receptor (ER) pathway plays a pivotal role in breast cancer development and
progression. Endocrine therapy to block the ER pathway is highly effective, but its …

The importance and role of the estrogen receptor (ER) pathway has been well-documented
in both breast cancer (BC) development and progression. The treatment of choice in women …